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Abstract
Spleen Tyrosine Kinase (SYK) was recently identified as a new target in acute myeloid leukemia
(AML); however, its mechanistic role in this disease is poorly understood. Based on the known
interaction between SYK and mTOR signaling in lymphoma, we hypothesized that SYK may
regulate mTOR signaling in AML. Both small-molecule inhibition of SYK and SYK-directed
shRNA suppressed mTOR and its downstream signaling effectors, as well as its upstream
activator, AKT. Moreover, the inhibition of multiple nodes of the PI3K signaling pathway
enhanced the effects of SYK suppression on AML cell viability and differentiation. Evaluation of
the collateral MAPK pathway revealed a heterogeneous response to SYK inhibition in AML with
down-regulation of MEK and ERK phosphorylation in some AML cell lines but a paradoxical
increase in MEK/ERK phosphorylation in RAS-mutated AML. These studies reveal SYK as a
regulator of mTOR and MAPK signaling in AML and demonstrate that inhibition of PI3K
pathway activity enhances the effects of SYK inhibition on AML cell viability and differentiation.
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tIntroduction
Acute myeloid leukemia (AML), the most common form of acute leukemia in adults,
continues to have poor survival rates. The overall five-year survival for adults under 50
years is approximately 50% and for those over 65 years is less than 20%.1 New and less
toxic approaches to treat AML are needed. With the success of all-trans retinoic acid
(ATRA) as a differentiating agent for acute promyelocytic leukemia (APL), there has been
interest in identifying new pro-differentiating compounds effective in the non-APL AML
subtypes.2 Because the targets of differentiation in AML remain largely unknown, or
pharmacologically intractable, and because the differentiation phenotype is complex, our
laboratory developed a new gene expression-based approach to compound discovery called
Gene Expression-based High-throughput Screening (GE-HTS). This chemical genomics
approach, integrated with proteomics and shRNA screening, previously identified spleen
tyrosine kinase (SYK) as a candidate pro-differentiating target in AML.3–5
SYK is a non-receptor tyrosine kinase that is broadly expressed in hematopoietic cells and is
an important mediator of signal transduction and differentiation, particularly in B-cell
development.6 The importance of SYK in hematological malignancies has been recognized
in lymphoma, leukemia, and myelodysplastic syndrome (MDS). In peripheral T-cell
lymphoma, recurrent ITK-SYK translocations have been reported,7 and conditional
expression of ITK-SYK in mice induces highly malignant peripheral T-cell lymphoma with
100% penetrance.8 In diffuse large B-cell lymphoma (DLBCL), SYK-dependent tonic B-
cell receptor signaling has been recognized as an important survival pathway,9 and in pre-B
cells, deregulated SYK has been reported to inhibit differentiation and induce growth factor
independence.10 Moreover, in a clinical trial, SYK inhibition had activity in patients with
non-Hodgkin's lymphoma and chronic lymphocytic leukemia.11 A role for SYK in myeloid
malignancies was first suggested with the report of a fusion of TEL to SYK in a patient with
MDS with t(9;12)(q22;p12).12 Importantly, this TEL-SYK fusion transforms the
interleukin-3 (IL-3) dependent murine hematopoietic cell line Ba/F3 to growth factor
independence.12 We identified AML as another hematologic malignancy in which SYK
plays an important role.3
While we have established that targeting SYK reduces viability and promotes differentiation
in AML, little is known about the downstream signaling effectors of SYK in AML. There is
a significant body of literature documenting the role of SYK in non-Hodgkin's lymphoma,
which has served as a useful framework for investigating SYK in AML.8, 9, 11, 13–16 In B-
cell lymphoma, SYK has been demonstrated to be a critical regulator of mTOR
activity.14, 17 mTOR positively regulates protein synthesis by activating two primary
signaling branches: p70S6K/RPS6 and 4E-BP1/eIF4E.18 This regulation, in turn, controls
cap-dependent translation of mRNAs with highly structured 5' UTRs, a feature characteristic
of transcripts for many oncogenic proteins. There has been much interest in mTOR as a
target in AML. mTOR has been found to be constitutively activated in the majority of
primary AML blasts, and it has been shown to be important for AML cell survival after
etoposide treatment.19 Furthermore, the inhibition of mTOR in AML has been associated
with both anti-proliferative and pro-differentiating effects 19–25 and mTOR inhibitors are
now being tested in patients with AML.23, 26–29
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tIn light of the evidence that SYK has been shown to activate mTOR in lymphoma and that
mTOR plays an important role in AML, we hypothesized that SYK may also regulate
mTOR signaling in AML. Here, we test this hypothesis using both chemical and genetic
inhibition of SYK to assess the effects on mTOR and its upstream activators and
downstream signaling effectors. We demonstrate that inhibition and constitutive activation
of SYK lead to corresponding inhibition and activation of mTOR signaling and that
concurrent inhibition of SYK and the PI3K pathway can promote differentiation and inhibit
viability in AML cells. Moreover, we reveal a heterogeneous response in the collateral
MAPK pathway to SYK inhibition in AML, with down-regulation of MEK and ERK
phosphorylation in some AML cell lines but a paradoxical increase in phosphorylation in
RAS-mutated AML.
Materials and Methods
Cell Culture
HL-60, U937, and KG-1 were purchased from the American Type Culture Collection
(ATCC) (Manassas, VA, USA). THP-1 and MOLM-14 were kindly provided by Dr. Scott
Armstrong and NOMO-1 by Dr. Ross Levine. Some of the well characterized genetic
features of these cell lines include: HL-60 (NRAS mutation30), U937 (CALM-AF10
rearrangement31) KG-1 (FGFR1OP2-FGFR1 rearrangement32), THP-1 (MLL-AF9
rearrangement,33NRAS mutation34), MOLM-14 (MLL-AF9 rearrangement,35FLT-3 ITD36),
and NOMO-1 (KRAS mutation37). All cell lines were maintained in RPMI 1640 (Cellgro,
Manassas, VA, USA) supplemented with 1% penicillin-streptomycin and 10% fetal bovine
serum (Sigma-Aldrich, St. Louis, MO, USA) at 37°C with 5% CO2. Primary patient AML
blasts were collected from peripheral blood or bone marrow aspirate after obtaining patient
informed consent under Dana-Farber Cancer Institute Internal Review Board-approved
protocols. Mononuclear cells were isolated using Ficoll-Paque Plus (Amersham
Biosciences) and red blood cells lysed before staining for flow cytometry analysis.
Chemicals
R940406 (R406, the active metabolite of fostamatinib) (supplied by Rigel Pharmaceuticals,
Inc., South San Francisco, CA, and AstraZeneca Pharmaceuticals, Wilmington, DE, USA),
rapamycin (Santa Cruz Biotechnology, Inc., Dallas, Texas, USA) and PD0325901 (Selleck,
Houston, Texas, USA) were resuspended in dimethyl sulfoxide (DMSO) (Sigma-Aldrich)
and stored at −80°C. 4EGI-1 (kindly provided by Dr. Gerhard Wagner), ATRA (Sigma-
Aldrich), Torin 1 (Tocris, Bristol, UK), GDC-0941 (Selleck) and Syk Inhibitor IV, BAY
61-3606 (EMD Biosciences, Darmstadt, Germany) were dissolved in DMSO and stored at
−20°C.
Immunoblotting
Cells were lysed using Cell Signaling Lysis Buffer (Cell Signaling, Danvers, MA, USA)
containing Complete, EDTA-free Protease Inhibitor Cocktail Tablet (Roche, Indianapolis,
IN, USA) and PhosSTOP Phosphatase Inhibitor Tablet (Roche) for protein extraction, as per
the manufacturer's instructions. Protein was quantified, resolved by gel electrophoresis, and
transferred to nitrocellulose membranes (BioRad Laboratories, Hercules, CA, USA). Blots
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twere incubated with primary antibodies to p-SYK (Tyr525/526) (Cell Signaling 2710), p-
mTOR (Ser2448) (Cell Signaling 2971), p-RPS6 (Ser240/244) (Cell Signaling 2215), p-4E-
BP1 (Thr37/46) (Cell Signaling 2855), p-AKT (Ser473) (Cell Signaling 4060), p-p44/42
MAPK (Erk1/2) (Thr202/Tyr204) (Cell Signaling 4370), p-MEK1/2 (Ser217/221) (Cell
Signaling 9154), p-c-RAF (Ser338) (Cell signaling 9427), total SYK (Santa Cruz
Biotechnology, SC-1240) (Santa Cruz, CA, USA), total mTOR (Cell Signaling 2972), total
RPS6 (Cell Signaling 2217), total 4E-BP1 (SC-81149), total 4E-BP1 (Cell Signaling 9644),
total AKT (Cell Signaling 2920), total p44/42 MAPK (Erk1/2) (Cell Signaling 4696), total
MEK1/2 (Cell Signaling 4694), GAPDH (Cell Signaling 2118), total c-RAF (Cell Signaling
9422), and Vinculin (Abcam, ab18058) (Cambridge, MA, USA). After incubation in
primary antibody for two hours at room temperature, blots were washed and incubated in
secondary anti-rabbit-HRP (Amersham #NA9340V) (Piscataway, NJ, USA) or anti-mouse-
HRP antibodies (Amersham #NA9310V) for one hour at room temperature. Bound antibody
was detected by chemiluminescence using either Western Lightning Plus ECL
(PerkinElmer, Inc., Waltham, MA, USA) or SuperSignal West Dura Extended Duration
Substrate (ThermoScientific, Rockford, IL, USA).
Phospho-specific Flow Cytometry
All flow cytometry studies using fluorophore-conjugated primary antibodies were conducted
with reagents and protocols from BD Biosciences (San Jose, CA, USA). The intracellular
phospho-specific flow protocol used was Protocol III (Mild or Harsh Alcohol Method) for
human peripheral blood mononuclear cells per the manufacturer's instructions. Flow
cytometric analysis was performed using the BD FACS Canto II flow cytometer. Cells were
gated by forward and side scatter to select viable cells for analysis. Data were analyzed with
the FlowJo Tree Star software package (Ashland, OR, USA). Antibodies used were
purchased from BD Biosciences and included p-RPS6 (pS240) (560430), p-4E-BP1 (pT36/
pT45) (560285), and total-SYK (552476). Antibody anti-p-SYK (Y525/526) was purchased
from Cell Signaling Technology (6485). For the primary patient AML/MDS studies, ficoll
separated mononuclear cells were incubated for 45 minutes with a combination of anti-
human PE-Cy7 CD13 (eBioscience # 25-0138-41) and anti-human PE-Cy7 CD33
(eBioscience # 25-0338-41) (used at 1/50) or PE-Cy7 isotype control antibodies before
staining with anti-phospho-antibodies. Effects of R406 on p-RPS6, p-4E-BP1 and pSYK, in
the CD13 and/or CD33 positive population of cells, were determined.
Morphological Evaluation
Cytospin preparations were performed with a Thermo Scientific Shandon Cytospin 4
instrument (Rockford, IL, USA). May Grunwald Giemsa staining (Sigma-Aldrich) was used
to assess changes in cellular morphology. Stained cells were examined by light microscopy
at 400× magnification with an Olympus BX41 microscope (Center Valley, PA, USA) and
Q-capture software (Surrey, BC, Canada).
Gene Expression-based High-throughput Screening (GE-HTS)
GE-HTS was conducted using methods previously described to assess for an expression
signature composed of genes that distinguish AML from either the neutrophil or monocyte
differentiated state.5, 38 The 32 marker genes for myeloid differentiation were chosen using
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tpreviously published Affymetrix AML-related data sets (Supplementary Table S1).5 These
genes have been shown to distinguish AML from either neutrophil or monocyte with p <
0.05 by t-test and to distinguish undifferentiated versus HL-60 differentiated with ATRA
(Sigma-Aldrich), phorbol 12-myristate 13-acetate, or 1,25-dihydroxyvitamin D3 with p <
0.05 by t-test. The GE-HTS assay was performed as detailed in the Supplemental
Experimental Procedures in Hahn et al., 2009.3 This assay uses ligation-mediated
amplification with a fluorescent bead-based detection system to quantify the expression of
up to 500 genes in a single well. Two primary scoring methods were used to quantify
induction of the 32-gene myeloid differentiation signature.3, 5 The Summed Score combines
expression ratios (marker gene/control gene) by summing them with a sign determined by
the expected direction of regulation from ATRA-treated positive controls. The Weighted
Summed Score combines expression ratios by summing them with a weight and sign
determined by the signal-to-noise ratio of each expression ratio for the positive control
(ATRA-treated) and negative control (DMSO-treated) samples. To assess the statistical
significance of the differences between these differentiation scores a one-way ANOVA with
a Bonferroni correction was employed.
Flow Cytometric Analysis of Activated Caspase 3, BrdU Incorporation and CD14/CD11b
Expression
Cells were washed with ice-cold PBS and then stained with a cocktail of CD11b-FITC /
CD14-PE (Beckman Coulter) antibodies diluted in PBS 2 mM EDTA 0.2% BSA. After
fixation and permeabilization with Cytofix/Cytoperm solution (BD Bioscience) and two
washes with Perm/Wash solution (BD Bioscience), cells were incubated for 30 min with
anti-active-caspase-3-APC monoclonal antibody (BD Pharmingen). Finally, cells were
washed and resuspended in Perm/Wash solution before being analyzed using the BD FACS
Canto II flow cytometer.
BrdU staining was performed using FITC BrdU Flow Kit (BD Pharmingen) per the
manufacturer's instructions.
Viability Assay
Viability experiments were performed using the Promega Cell-Titer Glo ATP-based assay
(Madison, WI, USA) per the manufacturer's instructions. Luminescence was measured using
a Fluostar Omega by BMG-labtech (Cary, NC, USA). Results were assessed using an excess
above Bliss additivism model. This model predicts the combined response, C, of two
individual agents with the effects A and B using the formula C = A + B − A × B.39, 40
Lentiviral Vectors and Infection
Oligonucleotides encoding shRNAs were cloned into pLKO.1 as described previously.41
The SYK-directed shRNAs chosen for study included SYK_1,
CCGGGCAGGCCATCATCAGTCAGAACTCGAGTTCTGACTGATGATGCCTGCTTT
TT and SYK_10,
CCGGGCAGCAGAACAGACATGTCAACTCGAGTTGACATGTCTGTTCTGCTGCTT
TTTTG, the shRNAs previously confirmed to yield efficient knockdown of SYK,3 and a
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tcontrol shRNA,
CCTAAGGTTAAGTCGCCCTCGCTCGAGCGAGGGCGACTTAACCTTAGGTTTTT
293T cells were used to produce lentivirus containing the desired SYK-directed shRNA
plasmid. Specifically, 500,000 293T cells were plated in 6 cm plates and transfected 24 hr
later with 1 μg of DNA from the lentiviral backbone vector and packaging plasmids
(pCMVdeltaR8.91 and pCMV-VSV-G) according to the FuGENE 6 (Roche) protocol.
Medium was changed to RPMI 1640 (Cellgro) 24 hours post-transfection, and viral
supernatant was harvested and filtered 48 hours post-transfection. Cells were infected for 2
hr at 37°C with 2 ml of lentivirus and 8 μg/ml polybrene (Sigma-Aldrich). Cells were
selected 48 hr later with 1 μg/ml puromycin (Sigma-Aldrich).
To generate the SYK-TEL construct, RT-PCR was used to isolate the sequence encoding
amino acids 1–336 of human ETV6 (TEL) and the full length sequence of human SYK. The
assembled cDNA was subcloned from the full-length sequence of SYK into a pWZL-Neo
Retroviral vector (Cell Biolabs, Inc. San Diego, CA). The SYK-TEL kinase dead (KD)
construct was generated by point mutation (K402R) in the kinase domain of SYK, using a
QuikChange XL Site-directed mutagenesis kit (Stratagene). The primer sequences used to
generate these mutants were 5'-GTG AAA ACC GTG GCT GTG CGA ATA CTG AAA
AAC GAG GC and 5'-GCC TCG TTT TTC AGT ATT CGC ACA GCC ACG GTT TTC
AC. The pLenti 6.2 vector encoding V5-tagged full length SYK was generated by
performing an LR recombination reaction between the pENTR/SD/D-TOPO entry vector
containing the wildtype, full length, sequence of SYK and the pLenti 6.2/V5-DEST
Gateway destination vector.
Results
Overexpression of SYK leads to increased activation of mTOR and MAPK signaling in AML
Because SYK has been reported to regulate mTOR in lymphoma, we investigated whether
this relationship was also present in AML where little is known about SYK's downstream
effectors. We also tested the effects of SYK signaling on the collateral MAPK pathway,
known to interact with PI3K/AKT/mTOR signaling. First, we overexpressed wildtype SYK,
SYK-TEL (a constitutively activated form of SYK), and kinase dead SYK-TEL in the AML
cell line MOLM-14. Both the mTOR pathway, including the upstream activator AKT and
downstream effectors, and the MAPK pathway were activated with expression of either
wildtype SYK or SYK-TEL but not kinase-dead SYK-TEL (Figure 1), suggesting that
enhanced activation of these two pathways is dependent on the kinase activity of SYK.
Chemical or genetic suppression of SYK inhibits AKT/mTOR in AML cell lines
We first identified AML cell lines with high levels of AKT activation (Supplementary
Figure S1) and treated two of these (MOLM-14 and U937) with R940406 (R406), an ATP-
competitive inhibitor of phosphorylation at the Y525/526 activation site of SYK
(Supplementary Figure S2a). R406 is the active metabolite of fostamatinib, a soluble orally
dosed prodrug converted to R406.42 Treatment with R406 led to a dose-response in the
inhibition of p-AKT and p-mTOR in both cell lines, indicating that SYK may be signaling
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tupstream of p-AKT in AML (Figure 2a and b). In MOLM-14 cells, total AKT was seen to
decrease along with p-AKT after a 24 hour treatment. In light of this observation, we
evaluated a shorter compound exposure of 6 hours and observed a decrease in
phosphorylated, but not total, AKT (Supplementary Figure S2b). This inhibition was seen as
early as 30 minutes post-treatment for p-AKT and p-mTOR. mTOR activation is commonly
evaluated by assessing the phosphorylation status of its two major downstream targets:
p70S6K/RPS6 and 4E-BP1/eIF4E. While inhibition of RPS6 phosphorylation was seen at 30
minutes, phosphorylation of the downstream effector 4E-BP1 was only minimally inhibited
until the 24 hour time point (Supplementary Figure S2c).
We next investigated the effects of SYK knockdown on AKT/mTOR activation using two
previously validated SYK-directed shRNAs.3 Both AKT and mTOR activation were
downregulated in parallel with diminished levels of SYK, indicating that this effect is likely
on-target for SYK (Figure 2c). In contrast, inhibition of the PI3K/mTOR pathway did not
have a positive feedback effect on SYK with no increase in SYK phosphorylation observed
with the PI3K inhibitor GDC-0941 nor the mTORC1/2 inhibitor Torin1 at concentrations
altering phosphorylation of target effector proteins (Supplementary Figure S3a and b).43
mTOR signaling effectors are differentially regulated by SYK in AML
Effects of SYK inhibition on p70S6K/RPS6 and 4E-BP1/eIF4E were next assessed across a
larger panel of AML cell lines by immunoblotting. RPS6 phosphorylation was
downregulated by R406 treatment (Figure 3a), while the effects of R406 on the
phosphorylation status of 4E-BP1 were more variable across the cell lines (Figure 3b). In
order to quantify the phosphorylation status of RPS6 and 4E-BP1, single cell intracellular
phospho-specific flow cytometry was used. Again, there was consistent inhibition of RPS6
across all cell lines while the inhibition of 4E-BP1 was more subtle in some cell lines and
absent in others (Supplementary Figure S4). In order to ensure that these effects were
reflective of primary human AML rather than simply a feature of cultured cell lines, we next
extended testing to primary patient AML and MDS. We used intracellular phospho-specific
flow cytometry to best quantify the effect of SYK inhibition given the limited number of
total cells in each primary sample. As was seen in the AML cell lines, a strikingly similar
pattern of consistently altered RPS6 phosphorylation, with more variable inhibition of 4E-
BP1 phosphorylation, was observed in five primary patient AML/MDS samples treated with
R406 (Figure 3c; Supplementary Table S2).
To investigate the specificity of SYK's differential effects on RPS6 and 4E-BP1, the
phosphorylation status of these targets was interrogated using two SYK-directed shRNAs.
While RPS6 was consistently inhibited with SYK knockdown, 4E-BP1 was more minimally
inhibited and in only a subset of the cell lines analyzed (Supplementary Figure S5).
Chemical inhibition of PI3K pathway signaling enhances the effects of SYK suppression
on differentiation and viability in AML
Because SYK inhibition appeared to affect the p70S6K/RPS6 mTOR axis to a greater
degree than the 4E-BP1/eIF4E axis in some AML cell lines, we hypothesized that more
complete inhibition of PI3K/mTOR signaling would synergize with SYK inhibition in AML
Carnevale et al. Page 7
Leukemia. Author manuscript; available in PMC 2014 May 21.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tin both its pro-differentiation and anti-viability effects. We thus evaluated in AML cell lines
the combination of SYK suppression with small-molecule modulators of the PI3K/mTOR
pathway: PI3K (GDC-0941), mTORC1/2 complex (Torin 1), and 4E-BP1 (4EGI-1). We
chose compound concentrations reported and confirmed to inhibit the intended pathways
targeted by the molecules (Supplementary Figures S3 and S6).43, 44 While Torin 1 treatment
led to a marked decrease in 4E-BP1 phosphorylation in AML, GDC-0941 treatment led to
only a modest reduction in phosphorylation of 4E-BP1 despite near complete inhibition of
AKT phosphorylation (Supplementary Figures S3 and S6). The compound 4EGI-1 mimics
hypophosphorylated 4E-BP1 by binding and inhibiting eIF4E's association with other
factors in the initiation complex, thus suppressing cap-dependent translation.45 Previous
studies demonstrated that 4EGI-1 displaces eIF4G from eIF4E at approximately 25–50
μM.45 Dose-finding analyses using an ATP-based viability assay revealed the IC50's for
4EGI-1 in the majority of AML cell lines tested to be within this range (data not shown).
As shown in Figure 4a, by day 6 there was a viability disadvantage to those cells with both
SYK knockdown and exposure to the small-molecule treatments greater than with any one
perturbation alone. We next evaluated the combined effects on differentiation focusing on
the small molecule expected to be most specific for inhibition of 4E-BP1, 4EGI-1, and AML
cell lines known to differentiate with ATRA and SYK inhibition, HL-60 and U937.3
Morphologic analyses reveal an enhanced level of nuclear condensation and cytoplasmic
ruffling in the conditions combining SYK knockdown and chemical inhibition of 4E-BP1
(Figure 4b). To more effectively quantify the induction of differentiation, we utilized an
assay measuring a 32-gene expression signature for myeloid differentiation previously
developed by our laboratory (Supplementary Table S1).3, 5 The combination of SYK-
directed shRNAs and 4EGI-1 resulted in a myeloid differentiation score higher than control
shRNA with 4EGI-1 or the SYK-directed shRNA with DMSO in HL-60 and U937 cells
consistent with the morphological findings (Figure 4c). In both cell lines the combination
score approached that of the positive control, ATRA.
Pharmacologic inhibition of SYK and eIF4E enhances differentiation and has a synergistic
effect on viability in AML
We next evaluated the effects of the most direct inhibitor of eIF4E, 4EGI-1 in combination
with R406. As in the combination of shRNA-directed against SYK with 4EGI-1 treatment, a
greater proportion of cells exposed to both compounds showed morphological evidence of
myeloid differentiation and an increased differentiation score compared to cells exposed to
R406 alone or 4EGI-1 alone (Figures 5a and b). When evaluated on a gene-by-gene level,
the effects of the compounds varied. In some cases, they affected the same genes with an
amplified effect when combined, and in other cases, they altered the expression of a unique
set of genes in the differentiation signature (Supplementary Figure S7). Combination
treatment with R406 and 4EGI-1 in AML cell lines was also performed across a range of
concentrations in 384-well format and synergy assessed using excess over Bliss additive
synergy analysis.40, 46 The Bliss model calculates an expected effect of the combined
response, C, of two individual agents with the effects A and B using the formula C = A + B
− A × B. Figure 5c shows, for a range of concentrations of the combination of the two
agents, the values for excess over Bliss or the difference between the effect measured and
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tthe effect predicted by the Bliss model.39, 40 Interestingly, this synergy did not occur
through enhancement of apoptosis but was dependent on an induction of CD11b/CD14-
positive myeloid differentiation and a decrease in proliferation as evidenced by diminished
BrdU incorporation (Supplementary Figure S8).
Effects of SYK signaling on the MAPK pathway are heterogeneous in AML
The MAPK pathway is known to interact with PI3K/mTOR signaling. Given that
constitutive activation of SYK resulted in activation of the MAPK pathway in AML we
explored the effects of SYK inhibition on MAPK effectors in a panel of AML cell lines.
Treatment of AML cell lines with R406 resulted in a decrease in phosphorylation of MEK
and ERK in many of the AML cell lines, while an unexpected increase in phosphorylation
was seen in HL-60 (Figure 6a). Because HL-60 is an N-RAS mutated cell line we
hypothesized that the increase in output through MAPK was related to the RAS status of this
cell line.30 Indeed, in both the N-RAS mutated cell line THP-134 and the K-RAS mutated line
NOMO-1,37 we observed a similar increase in signaling through the MAPK pathway with
R406 treatment (Figure 6b). This increase in MAPK activation seen in RAS-mutated AML
cell lines was observed with a second SYK inhibitor, BAY 61-3606 (data not shown). In
order to explore the potential mechanism for this paradoxical increase in ERK signaling in
RAS-mutated AML, we next assessed the involvement of c-RAF activation by R406. We
observed a decrease in c-RAF phosphorylation in the RAS-wild-type cell line MOLM-14,
which was absent in the RAS-mutated AML cell line HL-60 (Figure 6c) suggesting the
possibility of a feedback loop through c-RAF. MEK inhibition with PD0325901 blocks this
feedback activation of ERK, while the PI3K inhibitor GDC-0941 does not (Supplementary
Figure S9).
Discussion
Much progress has been made in understanding the biological mechanisms underlying the
pathogenesis of AML, yet poor survival rates indicate that new treatment strategies are
needed. Our laboratory recently validated SYK as a new target in AML. While little is
known about the downstream signaling effectors of SYK in AML, we leveraged knowledge
derived from studies of SYK in B-cell signaling and lymphoma to generate hypotheses
about its role in AML. One SYK target reported in non-Hodgkin's lymphoma, mTOR, was
of particular interest given the growing evidence of the critical role of mTOR in AML.
Moreover, previous studies of pathway activation downstream of the constitutively active
TEL-SYK fusion (identified in a patient with MDS) implicated a number of AML-relevant
pathways, including PI3K, MAPK, and JAK-STAT.47 Here, we provide evidence that SYK
regulates mTOR signaling in AML.
mTOR is a serine/threonine kinase that plays an important role in the regulation of a variety
of cellular processes required for tumor development, such as growth, proliferation, and
translational initiation of key proteins, including numerous, well-known oncogenes.48
mTOR is frequently deregulated in the majority of hematologic malignancies.19, 23, 49 There
has been growing interest in the role of mTOR in AML, where mTOR inhibition has been
associated with both antiproliferative and pro-differentiating effects. Specifically, mTOR
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tinhibitors have been shown to reduce AML clonogenicity and proliferation in vitro, as well
as regulate AML stem cell survival in animal models of engraftment.19, 23–25, 48, 50
Moreover, these molecules are being tested in patients with either refractory/relapsed, de
novo, or secondary AML with promising results in early clinical trials.23, 26–29 Furthermore,
blockade of mTOR signaling has been shown in multiple studies to potentiate the ability of
histone deacetylase inhibitors, 1,25-dihydroxyvitamin D3 and ATRA to induce
differentiation in AML.21, 22, 51 The precise mechanism by which mTOR inhibition leads to
this enhanced differentiation is not yet established although there have been some recent
clues regarding potential mechanisms, such as mTOR's regulation of c-MYC and
Programmed Cell Death-4 (PDCD4).52–54
Given the mounting interest in targeting mTOR in AML, as well as previous reports of SYK
regulation of mTOR in lymphoma, we chose to test whether SYK regulates mTOR in AML.
We demonstrated that chemical inhibition of SYK by R406 leads to the inhibition of p-
mTOR in multiple AML cell lines in a dose-dependent manner. Moreover, we showed that
genetic inhibition of SYK by shRNA and expression of wildtype SYK or constitutively
active SYK-TEL leads to inhibition and up-regulation of p-mTOR, respectively. We further
studied the activation of specific mTOR signaling branches, including p70S6K/RPS6 and
4E-BP1/eIF4E. Interestingly, the p70S6K/RPS6 signaling pathway was affected by
manipulations in SYK activity to a greater extent than the 4E-BP1/eIF4E pathway in some
AML cell lines and in primary patient AML and MDS cells. Within the framework of
canonical mTOR signaling diagrams, our data suggest a variable effect of SYK on p70S6K/
RPS6 and 4E-BP1 activation. This is not the first observation of downstream targets of
mTOR being regulated asymmetrically. For instance, in an mTOR independent manner,
phospholipase D-2-derived phosphatidic acid directly binds and activates p70S6K,55 and
p90 ribosomal S6 kinases directly phosphorylate RPS6.56 Others have identified the
activation of 4E-BP1 by the kinase PIM-2,57, 58 and regulation of eIF4E by MAP kinase-
interacting kinase 1 (MNK1).59 It is also apparent that diverse stimuli, such as insulin or
amino acid withdrawal, affect these branches in different ways depending on the cellular
context.60 It has been reported that in AML, mTORC1 inhibition by either the rapamycin
derivative, RAD001, or an siRNA directed against RAPTOR fails to effectively inhibit 4E-
BP1 phosphorylation.58 We have confirmed this finding in two AML cell lines using
rapamycin (Supplementary Figure S10a). Thus, regulation of mTOR signaling is quite
complex, and it is likely that there are different signals working with SYK to affect the
activation of p70S6K/RPS6 and 4E-BP1/eIF4E. While it is unclear how SYK regulates
p70S6K/RPS6 with greater magnitude and consistency than 4E-BP1 in some AML cell lines
and primary patient samples, this observation allowed the assessment of combining a SYK
inhibitor and an eIF4E inhibitor on AML viability and differentiation.
Our results revealed that combined chemical inhibition of SYK and eIF4E had a synergistic
effect on AML viability across multiple AML cell lines. Furthermore, eIF4E inhibition
enhanced the inhibitory effects of SYK knockdown on cell viability, suggesting that this
synergistic relationship with small-molecule inhibition of SYK is on-target. eIF4E inhibition
also enhanced AML differentiation when combined with SYK inhibition by either chemical
or SYK-directed shRNA. There is evidence that the 4E-BPs and eIF4E play pivotal roles in
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tmyeloid differentiation,61–63 and our own data suggests that inhibition of 4E-BP1/eIF4E
promotes greater differentiation than inhibition of RPS6 alone (Supplementary Figure
S10b). The mechanism responsible for this synergistic effect, however, is not clear. More
complete inhibition of both arms of the PI3K/mTOR signaling pathway could explain these
findings as both PI3K and mTORC1/2 small-molecule inhibitors also enhanced the anti-
AML effects of SYK-directed shRNA. It is also possible that there are downstream targets
upon which SYK and mTOR converge and that this combined inhibition confers a more
potent AML differentiation effect. Indeed, while SYK inhibition leads to a decrement in
RPS6 phosphorylation in U937 and HL-60, SYK inhibition promotes greater differentiation
than RPS6 inhibition with rapamycin, suggesting that there are likely other RPS6
independent effects contributing to the differentiation induced by SYK inhibition in AML.
In evaluating pathways collaborating with PI3K, specifically MAPK, we made the
observation that with exogenous expression of activated SYK, MAPK signaling increases.
In contrast, with pharmacological inhibition of SYK, there is a decrease in phosphorylation
of MEK and ERK in a subset of AML cells, but in RAS-mutated AML cell lines, there is a
paradoxical increase in MEK/ERK activation seen with two structurally distinct SYK
inhibitors. This activation was inhibited by the MEK inhibitor PD0325901 but not the PI3K
inhibitor GDC-0941 (Supplementary Figure S9). Moreover, these RAS-mutated AML cell
lines are more resistant to the effects of pharmacologic inhibition of SYK on AML cell
viability.3 There have been similar observations of feedback activation of MAPK reported in
the context of other malignancies. For example, Carracedo et al. reported that inhibition of
mTORC1 leads to MAPK activation through a PI3K dependent feedback loop through S6K-
PI3K-RAS pathway in solid tumor samples from patients and in cancer cell lines and mouse
models of prostate cancer.64 In the case of SYK inhibition in AML, however, MEK
inhibition, but not PI3K inhibition, attenuates the feedback activation of MAPK. It is also
possible that this observation is secondary to an off-target effect of both of these small-
molecule inhibitors of SYK. It is noteworthy that RAF inhibitors can transactivate RAF
dimers and ERK signaling in the context of wildtype RAF expression, particularly in RAS-
mutated cell lines.65 While the precise mechanism of this observed phenomenon in AML
with SYK inhibition is still under consideration, these results suggest a cautionary use of
SYK inhibitors in patients with RAS-mutated AML, but also raise the possibility of
combining SYK inhibition with MEK inhibition for these patients, particularly because
MEK inhibition appears to attenuate this positive feedback on the MAPK pathway.
Here, we provide the first documentation that SYK regulates mTOR in AML and
demonstrate that combined inhibition of SYK and mTOR signaling has a synergistic effect
in AML. Moreover, the data suggest that the effects of SYK inhibition on MAPK are
variable with downregulation of MAPK signaling in some AML and a paradoxical
upregulation in RAS-mutated AML. This data may be of particular relevance for clinical
trials of SYK inhibitors in AML and for trials attempting to maximize SYK-inhibitory
effects with a combinatorial approach.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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A constitutively activated form of SYK and overexpressed wildtype SYK stimulate AKT/
mTOR and MAPK pathways. Western-blot of AKT/mTOR and MAPK downstream
effectors in MOLM-14 transduced with V5-tagged SYK, SYK-TEL or SYK-TEL KD (KD =
kinase dead).
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Chemical or genetic manipulation of SYK leads to altered AKT and mTOR activation.
Western blot of (a) p-AKT (Ser473) or (b) p-mTOR (Ser2448) in AML cell lines treated
with R406 for 24 hours. (c) AML cell lines MOLM-14 and U937 were infected with shRNA
targeting SYK or an shRNA control and assessed for levels of p-AKT and p-mTOR 5 days
post-infection.
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SYK inhibition with R406 inhibits downstream mTOR signaling targets in AML cell lines
and primary AML. Four AML cell lines (a and b) were treated for 24 hours with vehicle
versus R406. Western blots of (a) p-RPS6 (Ser240/244) and (b) p-4E-BP1 (Thr37/46) (c)
Intracellular phospho-flow cytometry of p-SYK, p-4E-BP1 and p-RPS6 in primary patient
AML and MDS cells treated for 6 hours with R406. The x-axis denotes expression (log
scale) for each protein of interest, and each is labeled with the median fluorescent intensity
(MFI) per condition.
Carnevale et al. Page 18
Leukemia. Author manuscript; available in PMC 2014 May 21.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tFigure 4.
Pharmacologic inhibition of AKT/mTOR enhances the effect of genetic inhibition of SYK
on viability and differentiation in AML. (a) AML cell lines infected with SYK-directed
shRNA or control shRNA were exposed to either DMSO, GDC-0941 (1 μM), Torin 1 (250
nM for HL-60 or 50 nM for U937), or 4EGI-1 (25 μM) and viability was assessed at 0, 3 and
6 days post treatment. Error bars denote the mean ±SD of 8 replicates with statistical
significance evaluated using a one-way ANOVA with a Bonferroni correction for each
compound at day 6. In each subpanel, all three brackets are significant with *** P < 0.001.
A summary of P values for Bonferroni multiple pairwise comparisons test is shown in
Supplementary Table S3. (b) HL-60 and U937 cells were infected with control shRNA or
SYK-directed shRNA and exposed to either DMSO or 4EGI-1 for three days. May Grunwald
Giemsa staining of HL-60 and U937 cells for each condition is depicted. Evidence of
myeloid maturation included a reduction in the nuclear to cytoplasmic ratio and an increase
in cytoplasmic ruffling. Images were acquired with an Olympus BX41 microscope, 400×
magnification, and Qcapture software. (c) HL-60 and U937 cells were infected with control
shRNA and SYK-directed shRNA and then exposed to either DMSO, 4EGI-1, or ATRA for
three days. The Differentiation Score (Weighted Summed Score) was quantified by the GE-
HTS approach. Error bars denote the mean ±SD of 8 replicates, and statistical significance
of the differences between these differentiation scores was derived using a one-way
ANOVA with a Bonferroni correction.
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Chemical inhibition of eIF4E by 4EGI-1 enhances the effect of chemical inhibition of SYK
on AML differentiation. (a) May Grunwald Giemsa staining of HL-60 and U937 cells
treated for 5 days with DMSO, R406, 4EGI-1, and in combination is depicted. (b) HL-60
and U937 cells were treated for three days with DMSO, R406, 4EGI-1, or the combination
of both compounds. A 32-gene differentiation signature was quantified by the LMA/bead-
based approach and a Weighted Summed Score (Differentiation Score) calculated for all
genes was determined for each condition. Error bars denote the mean ±SD of 8 replicates
and statistical significance of the differences between these differentiation scores was
derived using a one-way ANOVA with a Bonferroni correction. (c) The effects of
combining small-molecule inhibitors against SYK and eIF4E were assessed with an ATP-
based viability assay in two AML cell lines. Viability effects were assessed three days after
treatment with R406, 4EGI-1, both in combination and vehicle (DMSO) in replicates of four
for each dose combination for HL-60 while U937 was assessed at five days. The data was
analyzed using a Bliss additivism model.
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SYK inhibition with R406 alters downstream MAPK signaling targets. Six AML cell lines
were treated with vehicle versus R406. Western blots of p-MEK1/2 (Ser217/221) and p-
ERK1/2 (Thr202/Tyr204) and p-c-RAF (Ser338) are depicted. (a) HL-60, KG-1, MOLM-14
and U937 cells were treated for 6 hours for p-MEK1/2 analysis and 24 hours for p-ERK1/2
analysis. (b) NOMO-1 and THP-1 cells were treated for 24 hours. (c) Effect of SYK
inhibition on c-RAF in AML cells. AML cells were grown in the presence of 4 μM R406 for
the indicated times and assessed for activation of c-RAF and ERK1/2.
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